Oral Prophylactic Measures on the Occurrence of Pre-eclampsia (OP-PE)

Sponsor
Claude Bernard University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04989075
Collaborator
Cheikh Anta Diop University, Senegal (Other), University of Ouagadougou, Burkina Faso (Other)
880
1
2
18
48.8

Study Details

Study Description

Brief Summary

Pre-eclampsia (PE) remains a major source of maternal and perinatal morbidity and mortality especially in low- and middle-income settings. PE, a pregnancy-specific hypertensive disorder, characterized by the development of placental endothelial dysfunction resulting in, among the most common diagnostic features, concomitant hypertension and proteinuria that may evolve into organs with fluctuating clinical specificities. Current studies indicate that periodontal disorders during pregnancy and particularly periodontal pathogens may be related to the risk of PE. Standard oral hygiene methods, based mainly on the joint use of toothbrushes and interdental brushes, reduce periodontal inflammatory risk, modulate of the dysbiotic oral microbiome. The purpose of the present study is to compare the PE outcomes in high-risk pregnant women receiving oral prophylactic measures to a control group. One specific question is addressed as follows according to the PICO principles: In high-risk pregnant women (Population), does oral prophylactic measures (Intervention) have a beneficial effect on PE parameters (Outcome) compared to pregnant women without any specific oral prophylactic measures (Control)?

Condition or Disease Intervention/Treatment Phase
  • Other: Oral prophylactic intervention
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
880 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This trial is designed as an two-arm parallel cluster randomized controlled trial with antenatal obstetric clinic as the unit of randomisation and an allocation ratio of 1:1This trial is designed as an two-arm parallel cluster randomized controlled trial with antenatal obstetric clinic as the unit of randomisation and an allocation ratio of 1:1
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effect of Oral Prophylactic Measures on the Occurrence of Pre-eclampsia (OP-PE) in High-risk Pregnant Women: A Cluster-randomized Controlled Trial
Actual Study Start Date :
Mar 15, 2022
Anticipated Primary Completion Date :
Sep 15, 2022
Anticipated Study Completion Date :
Sep 15, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control group

The control group will continue its usual oral hygiene practice.

Experimental: Oral prophylactic intervention

For the study group, the oral prophylactic intervention will consist of provision of specfic package including soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.

Other: Oral prophylactic intervention
The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.

Outcome Measures

Primary Outcome Measures

  1. Incidence of pre-eclampsia from baseline during the pregnancy [9 months of pregnancy]

    To determine if pregnant women suffer from pre-eclampsia, several indices are measured (diastolic or systolic pressure and proteinuria or urinary protein/creatinine ratio). The combination of the results of pressure and proteinuria permits to classify of a woman as suffering from pre-eclampsia if: the diastolic pressure is higher than 90 mm Hg on two 4 hours intervals, or > 110 mm Hg once, or systolic pressure > 140 mm Hg on two 4 hours intervals, or > 160 mm Hg once, after 20 weeks of gestation and, the proteinuria measured is of 2+ or more, or > 300mg/24 hours, or > 500mg/L or urinary protein/creatinine ratio > 0.034g/mmol.

Secondary Outcome Measures

  1. Number of pathogenic bacteria in the interdental microbiota during the pregnancy [3 months, 6 months and 8 months of pregnancy]

    Quantitative PCR experiments will be performed and a quantitative analysis of the interdental microbiota will be made

  2. Change of pocket probing depth of teeth during the pregnancy [3, 4, 5, 6, 7, 8 and 9 months of pregnancy]

    Quantification of the pocket probing depth of the teeth with a periodontal probe

  3. Change of clinical attachment level of teeth during the pregnancy [3, 4, 5, 6, 7, 8 and 9 months of pregnancy]

    Quantification of the clinical attachment level of the teeth with a periodontal probe

  4. Change of gingival index of teeth during the pregnancy [3, 4, 5, 6, 7, 8 and 9 months of pregnancy]

    Quantification of the gingival index

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 35 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • pregnant woman

  • women from sub-Saharan Africa

  • aged from 18 to 35 years old

  • nullipares at the time of the obstetrical consultation

  • up to 12 weeks pregnant

  • acceptance of the terms and conditions of the study

  • signature of the informed consent form,

Exclusion Criteria:
  • fetal distress

  • congenital uterine and vaginal abnormalities

  • infectious or systemic diseases such as HIV, tuberculosis, candidiasis, cancers, hemopathies

  • premature termination of pregnancy for medical reasons

  • periodontal lesions of stage II, III (i.e., PD ≥ 4 mm, and/or CAL ≥ 4 mm), generalized (>30% of sites)

  • history or treatment of PD

  • a course of dental or orthodontic treatment

  • less than 20 natural teeth, excluding third molars

  • medication affecting the gum and/or oral mucosa

  • regularly using interdental brushes and/or dental floss and/or mouthwash

  • unable to answer questions or non-cooperative.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Dakar Senegal

Sponsors and Collaborators

  • Claude Bernard University
  • Cheikh Anta Diop University, Senegal
  • University of Ouagadougou, Burkina Faso

Investigators

  • Study Director: Florence Carrouel, Dr, P2S, UR4129, University of Lyon

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Carrouel Florence, Associate professor, Claude Bernard University
ClinicalTrials.gov Identifier:
NCT04989075
Other Study ID Numbers:
  • OP-PE
First Posted:
Aug 4, 2021
Last Update Posted:
Jul 21, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Carrouel Florence, Associate professor, Claude Bernard University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2022